Does nebivolol improve endothelial dysfunction and will it rescue the reputation of the beta-blockers in the future?
Celik
Turgay
T
Iyisoy
Atilla
A
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D001578:Benzopyrans / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D004730:Endothelium, Vascular / Q000187:drug effects*; D004983:Ethanolamines / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000068577:Nebivolol; D016032:Randomized Controlled Trials as Topic
D000319:Adrenergic beta-Antagonists; D001578:Benzopyrans; D004983:Ethanolamines; D000068577:Nebivolol